AVITA Medical, Inc. (FRA:51KA)

Germany · Delayed Price · Currency is EUR

2.920

-0.080 (-2.67%)

At close: Dec 4, 2025

-76.07% (1Y)

Market Cap	92.82M
Revenue (ttm)	61.71M
Net Income (ttm)	-41.38M
Shares Out	n/a
EPS (ttm)	-1.54
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	2.920
Previous Close	3.000
Day's Range	2.920 - 2.920
52-Week Range	2.920 - 13.300
Beta	n/a
RSI	20.70
Earnings Date	Feb 12, 2026

About AVITA Medical

AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company’s lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting devi... [Read more]

Industry Biological Products, Except Diagnostic Substances

CEO Cary Vance

Employees 260

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol 51KA

Full Company Profile

Financial Performance

In 2024, AVITA Medical's revenue was $64.25 million, an increase of 28.14% compared to the previous year's $50.14 million. Losses were -$61.85 million, 74.8% more than in 2023.

Financial numbers in USD Financial Statements

News

There is no news available yet.